Astellas Archives -

News/ News/ News/ Patients/ Sales and Marketing

Bayer tops pharma rankings for diversity, inclusivity

Phil Taylor alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva 0 Comment

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women

Bayer tops pharma rankings for diversity, inclusivity

https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/

News/ News/ R&D

Astellas teams up with UK biotech Mogrify on hearing loss project

Phil Taylor Astellas, cell therapy, hearing loss, Mogrify, otology, partnering, Regenerative medicine 0 Comment

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy

Astellas teams up with UK biotech Mogrify on hearing loss project

https://pharmaphorum.com/news/astellas-teams-up-with-uk-biotech-mogrify-on-hearing-loss-project/

News/ News/ Oncology

Astellas pumps $90m into Sutro immuno-oncology alliance

Phil Taylor antibody-drug conjugate, Astellas, immuno-oncology, Oncology, partnering, Sutro Biopharma 0 Comment

Astellas has agreed a $1.36 billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates

Astellas pumps $90m into Sutro immuno-oncology alliance

https://pharmaphorum.com/news/astellas-pumps-90m-into-sutro-immuno-oncology-alliance/

News/ News/ R&D

Another Astellas gene therapy hits a safety hurdle

Phil Taylor Astellas, gene therapy, Pompe disease, safety 0 Comment

The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA

Another Astellas gene therapy hits a safety hurdle

https://pharmaphorum.com/news/another-astellas-gene-therapy-hits-a-safety-hurdle/

Market Access/ News/ News

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

Phil Taylor anaemia, Astellas, chronic kidney disease, Evrenzo, HEOR, NHS, NICE 0 Comment

Astellas’ oral HIF-PH inhibitor Evrenzo has become the first drug in the class to be recommended for routine

NICE backs Astellas’ oral therapy Evrenzo for anaemia in kidney disease

https://pharmaphorum.com/news/nice-backs-astellas-oral-therapy-evrenzo-for-anaemia-in-kidney-disease/

News/ News/ News/ Oncology/ R&D

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

Phil Taylor acute myeloid leukaemia, Astellas, Daiichi Sankyo, EHA 2022, FLT3 inhibitor, Novartis, quizartinib, Rydapt, Xospata 0 Comment

Three years after Daiichi Sankyo’s FLR3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the

EHA: Survival data sets Daiichi Sankyo’s quizartinib back on track

https://pharmaphorum.com/news/eha-survival-data-sets-daiichi-sankyos-quizartinib-back-on-track/

News/ News/ News/ Oncology/ R&D

Astellas taps GO’s glycoprotein platform with $783.5m deal

Phil Taylor Astellas, glycoprotein, GO Therapeutics, immuno-oncology, Oncology, partnering 0 Comment

Astellas has become the latest big pharma company to sink some money into immuno-oncology start-up GO Therapeutics, forging

Astellas taps GO’s glycoprotein platform with $783.5m deal

https://pharmaphorum.com/news/astellas-taps-gos-glycoprotein-platform-with-783-5m-deal/

News/ News/ R&D

Astellas takes $170m charge as it drops DMD gene therapies

Phil Taylor Astellas, Duchenne muscular dystrophy, gene therapy, safety 0 Comment

Astellas has said it will book a $170 million impairment charge in its fourth quarter results as a

Astellas takes $170m charge as it drops DMD gene therapies

https://pharmaphorum.com/news/astellas-takes-170m-charge-as-it-drops-dmd-gene-therapies/

Deep Dive/ R&D/ Views & Analysis

Inside the changing tides of life science research

mike.hammerton@pharmaphorum.com Astellas, Bernhardt Zeiher, Deep Dive, Deep Dive: Research and Development, research and development 0 Comment

Astellas Pharma chief medical officer Bernhardt Zeiher talks about the evolution of R&D in life sciences Research and

Inside the changing tides of life science research

https://pharmaphorum.com/r-d/inside-the-changing-tides-of-life-science-research/

Trending

Astellas

Login